Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications

被引：9

作者：

Borad, M. ^{[1
]}

Javle, M. ^{[2
]}

Shaib, W. L. ^{[3
]}

Mody, K. ^{[4
]}

Bergamo, F. ^{[5
]}

Harris, W. P. ^{[6
]}

Damjanov, N. ^{[7
]}

Macarulla, T. ^{[8
]}

Brandi, G. ^{[9
]}

Masi, G. ^{[10
]}

Busset, M. Droz Dit ^{[11
]}

Boncompagni, A. ^{[12
]}

Dimova-Dobreva, M. ^{[12
]}

Engelhardt, M. ^{[12
]}

Saulay, M. ^{[12
]}

Halfdanarson, T. R. ^{[13
]}

Knox, J. ^{[14
]}

Abou-Alfa, G. K. ^{[15
]}

Personeni, N. ^{[16
]}

Mazzaferro, V. ^{[17
]}

机构：

[1] Mayo Clin Canc Ctr, Dept Oncol, Scottsdale, AZ USA

[2] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA

[3] Emory Univ, Hematol & Oncol, Atlanta, GA USA

[4] Mayo Clin, Hematol & Oncol, Jacksonville, FL USA

[5] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol 1, Padua, Italy

[6] Univ Washington, Med, Med Ctr, Seattle, WA USA

[7] Univ Penn, Abramson Canc Ctr, Hematol & Oncol, Philadelphia, PA USA

[8] Vall Hebron Inst Oncol, Med Oncol, VHIO Cellex Ctr, Barcelona, Spain

[9] Univ Bologna, Med Oncol, IRCCS Azienda Osped, Bologna, Italy

[10] AOU Pisana Stabilimento Santa Chiara, Oncol Med, Pisa, Italy

[11] Fdn IRCCS, Hepatopancreatobiliary & Digest Surg, Ist Nazl Tumori Milano, Milan, Italy

[12] Basilea Pharmaceut Ltd, Dept Dev, Basel, Switzerland

[13] Mayo Clin, Dept Med Oncol, Rochester, NY USA

[14] Princess Margaret Canc Ctr, Oncol Med, Toronto, ON, Canada

[15] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Dept Med, New York, NY USA

[16] Ist Clin Humanitas, Dept Oncol & Hematol, Rozzano, Italy

[17] Fdn IRCCS, Oncol Med, Ist Nazl Tumori Milano, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.087

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

59P

引用

页码：S567 / S568

页数：2

共 50 条

[21] Diverse Landscape of Fibroblast Growth Factor Receptor 2 (FGFR2) Rearrangement Partners in Intrahepatic Cholangiocarcinoma (iCCA)
Silverman, I. M.
Reeser, J. W.
Wing, M. R.
Krook, M. A.
Roychowdhury, S.
Newton, R. C.
Burn, T. C.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1185 - 1185
[22] Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Morizane, Chigusa
Valle, Juan W.
Karasic, Thomas B.
Abrams, Thomas A.
Kelley, Robin Kate
Cassier, Philippe
Furuse, Junji
Klumpen, Heinz-Josef
Chang, Heung-Moon
Chen, Li-Tzong
Komatsu, Yoshito
Masuda, Kunihiro
Ahn, Daniel
He, Yaohua
Soni, Nital
Benhadji, Karim A.
Bridgewater, John A.
CANCER RESEARCH, 2021, 81 (13)
[23] A pilot study of ponatinib in cholangiocarcinoma patients with FGFR2 fusions.
DeLeon, Thomas
Alberts, Steven R.
McWilliams, Robert R.
Hubbard, Joleen Marie
Ahn, Daniel H.
Bekaii-Saab, Tanios S.
Mody, Kabir
Roberts, Lewis R.
Salomao, Marcela
Kipp, Benjamin
Halfdanarson, Thorvardur Ragnar
Murtaza, Muhammed
Ramanathan, Ramesh K.
Dueck, Amylou C.
Borad, Mitesh J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[24] Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma
Saborowski, Anna
Vogel, Arndt
Segatto, Oreste
TRENDS IN CANCER, 2022, 8 (02) : 83 - 86
[25] Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements
Neuzillet, Cindy
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 773 - 775
[26] Cholangiocarcinoma: fusions in FGFR2 detected in liquid biopsy
Patriarca, M. E.
Coma, M. I.
Naranjo Hans, D.
Fernandez Rodriguez, M. C.
Bellosillo, B.
Visa Turmo, L.
Lloveras, B.
VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S245 - S246
[27] FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
Huang, X-W.
Shi, G-M.
Zhang, T.
Bao, L-Q.
Wen, T-F.
Zhang, B.
Peng, T.
Zhao, H.
Kuang, M.
Wang, W-L.
Ran, J-H.
Liu, Y-B.
Gong, W.
Mou, H-B.
Luo, Y.
Wang, Y.
Sun, H.
Fan, J.
Liu, L-X.
Dai, M.
ANNALS OF ONCOLOGY, 2021, 32 : S379 - S379
[28] Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
Li, Fangda
Peiris, Malalage N.
Donoghue, Daniel J.
CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 52 : 56 - 67
[29] Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIXCCA2
Morizane, Chigusa
Komatsu, Yoshito
Masuda, Kunihiro
Kanai, Masashi
Ioka, Tatsuya
Ueno, Makoto
Ozaka, Masato
Mizuno, Takashi
Sakai, Daisuke
Nakamura, Masafumi
Shimura, Masashi
Lipika, Goyal
Furuse, Junji
ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
[30] Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2-A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions/rearrangements
Valle, J. W.
Hollebecque, A.
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Morlock, R.
He, Y.
Benhadji, K.
Bridgewater, J.
ANNALS OF ONCOLOGY, 2020, 31 : S263 - S264

← 1 2 3 4 5 →